Related Experiment Video
Updated: Feb 28, 2026
09:48
Microcrystal Electron Diffraction of Small Molecules
Published on: March 15, 2021
7.2K
[Crystalline polymorphism of eflucimibe].
1Institut de Recherche Pierre Fabre, 17, avenue Jean Moulin, F 81106 Castres, France.
Annales Pharmaceutiques Francaises
|June 7, 2002
Summary
Researchers identified two crystalline polymorphic forms (A and B) of the drug eflucimibe. Form A is the more thermodynamically stable form under typical conditions, crucial for drug formulation and bioavailability.
Area of Science:
- Pharmaceutical Chemistry
- Solid-State Chemistry
Context:
- Understanding drug bioavailability and formulation quality is critical in therapeutics.
- Crystalline polymorphism significantly impacts drug properties and efficacy.
Purpose:
- To investigate the crystalline polymorphism of eflucimibe during its research phase.
- To characterize the different polymorphic forms using various analytical techniques.
Summary:
- Two distinct polymorphic forms of eflucimibe, designated A and B, were identified and characterized using X-ray powder diffraction (XRPD), differential scanning calorimetry (DSC), infrared spectrometry (IR), and solid-state nuclear magnetic resonance (SSNMR).
- Polymorph A exhibits specific thermal events related to conformational changes and phase transitions, while polymorph B shows distinct crystalline phase changes.
- Form A demonstrates higher thermodynamic stability within the 25-50°C range and lower solubility in ethanol compared to Form B, with an A<-->B transition temperature below 25°C.
Impact:
- This research provides foundational knowledge on eflucimibe's solid-state properties, essential for developing a stable and bioavailable drug product.
- The identification of the most stable polymorph aids in optimizing drug formulation and manufacturing processes.
- Understanding eflucimibe's polymorphism contributes to the successful development of this new chemical entity for therapeutic use.
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
54
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
54
01:27Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
209
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
209
01:21Factors Affecting Dissolution: Polymorphism, Amorphism and Pseudopolymorphism
791
Polymorphism refers to the existence of a drug substance in multiple crystalline forms, known as polymorphs. Recently, this term has been expanded to include solvates (forms containing a solvent), amorphous forms (non-crystalline forms), and desolvated solvates (forms from which the solvent has been removed).
Some polymorphic crystals possess lower aqueous solubility than their amorphous counterparts, leading to incomplete absorption. For instance, the oral suspension of Chloramphenicol, which...
Some polymorphic crystals possess lower aqueous solubility than their amorphous counterparts, leading to incomplete absorption. For instance, the oral suspension of Chloramphenicol, which...
791
01:10Recrystallization: Solid–Solution Equilibria
4.1K
Recrystallization is a purification technique used to separate impurities from solid compounds. In this technique, no chemical reactions occur. Instead, it exploits physical properties only, specifically, the solubility differences between the desired compound and impurities, either at a single temperature or at different temperatures, and under other selected conditions. The solid-solution equilibrium (solubility equilibrium) of each component in the solution represents a binary phase...
4.1K
01:21Polymer Classification: Crystallinity
4.1K
Unlike ionic or small covalent molecules, polymers do not form crystalline solids due to the diffusion limitations of their long-chain structures. However, polymers contain microscopic crystalline domains separated by amorphous domains.
Crystalline domains are the regions where polymer chains are aligned in an orderly manner and held together in proximity by intermolecular forces. For example, chains in the crystalline domains of polyethylene and nylon are bound together by van der Waals...
Crystalline domains are the regions where polymer chains are aligned in an orderly manner and held together in proximity by intermolecular forces. For example, chains in the crystalline domains of polyethylene and nylon are bound together by van der Waals...
4.1K
01:20Antiepileptic Drugs: Potassium Channel Activators
864
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
864